PharmaShots | Incisive News in 3 Shots

Subscribe Now

j&j

Johnson & Johnson Reports P-III (MARIPOSA) Trial Data of Rybrevant + Lazcluze for EGFRm NSCLC

Johnson & Johnson Reports P-III (MARIPOSA) Trial Data of Rybrevant + Lazcluze for EGFRm NSCLC

March 27, 2025

Johnson & Johnson Reports the US FDA’s Approval of Subcutaneous & Intravenous Tremfya for Active Crohn’s Disease (CD)

Johnson & Johnson Reports the US FDA’s Approval of Subcutaneous & Intravenous Tremfya for Active Crohn’s Disease (CD)

March 21, 2025

Johnson & Johnson Highlights P-III Clinical Data of Icotrokinra for Plaque Psoriasis at AAD 2025

Johnson & Johnson Highlights P-III Clinical Data of Icotrokinra for Plaque Psoriasis at AAD 2025

March 10, 2025

Johnson & Johnson MedTech Launches Shockwave Javelin Peripheral IVL Catheter in the US

Johnson & Johnson MedTech Launches Shockwave Javelin Peripheral IVL Catheter in the US

March 6, 2025

The US FDA Approves sNDA for J&J’s Spravato (esketamine) to Treat Major Depressive Disorder (MDD)

The US FDA Approves sNDA for J&J’s Spravato (esketamine) to Treat Major Depressive Disorder (MDD)

January 22, 2025

Johnson & Johnson Submits NDA to the US FDA for TAR-200 to Treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC)

Johnson & Johnson Submits NDA to the US FDA for TAR-200 to Treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR...

January 17, 2025

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us